Tectonic Therapeutic, Inc.
NGM: TECXLive Quote
About Tectonic Therapeutic, Inc.
Healthcare
Biotechnology
Tectonic Therapeutic, Inc., a biotechnology company, focuses on the discovery and development of therapeutic proteins and antibodies to modulate the activity of G protein coupled receptors (GPCRs). It develops GEODe technology platform to enable the discovery and development of GPCR-targeted biologic medicines. The company's lead product is TX45, a Fc-relaxin fusion molecule that activates the RXFP1 receptor, the GPCR target of the hormone, and relaxin. It is also developing TX2100 for the treatment of hereditary hemorrhagic telangiectasia; GPCR modulator bispecific for treating fibrosis; and other GPCR modulators. The company is headquartered in Watertown, Massachusetts.
📊 Fundamental Analysis
Tectonic Therapeutic, Inc. demonstrates a profit margin of 0.0%, which is below the sector average, suggesting competitive pressure.
Return on Equity (ROE) is -37.8%, which indicates that capital utilization is currently under pressure.
At a current price of $30.72, TECX currently sits at the 75th percentile of its 52-week range (Range: $14.39 - $36.03).
🏥 Financial Health
🔴
Profit Margin
Weak
⚠️
Debt/Equity
Moderate
🔴
Return on Equity
Weak
Key Financials
Market Cap
$538.90M
Trailing P/E
--
Forward P/E
-6.56
Beta (5Y)
--
52W High
$36.03
52W Low
$14.39
Avg Volume
372K
Day High
Day Low
📡 Subscribe to ZcoreAI updates
Join the list to get access to:
- Z-Score signals at market open
- New app features and updates
- Exclusive promo for ZcoreAI App